Pharmacokinetics/pharmacodynamics of vaborbactam, a novel beta-lactamase inhibitor, in combination with meropenem

Antimicrobial Agents and Chemotherapy

Volumn 63, Issue 1, 2019, Pages

  Griffith, David C ^a   Sabet, Mojgan ^a   Tarazi, Ziad ^a   Lomovskaya, Olga ^a   Dudley, Michael N ^a  

^a Medicines Company   (United States)

Author keywords

Enterobacteriaceae; Pharmacodynamics; Vaborbactam

Indexed keywords

MEROPENEM; VABORBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; BORONIC ACID DERIVATIVE; MEROPENEM AND VABORBACTAM; SINGLE HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DOSE REGIMEN; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; HOLLOW FIBER INFECTION; HUMAN; IN VITRO STUDY; INFECTION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; THIGH; THIGH INFECTION; ANIMAL; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; FEMALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PYELONEPHRITIS; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BORONIC ACIDS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; KLEBSIELLA PNEUMONIAE; MEROPENEM; MICE; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PYELONEPHRITIS; URINARY TRACT INFECTIONS;

EID: 85058925422     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01659-18     Document Type: Article

References (26)

1. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–10. https://doi.org/10.1086/516284.
2. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis 44:79–86. https://doi.org/10.1086/510079.
3. Bowker KE, Holt HA, Lewis RJ, Reeves DS, MacGowan AP. 1998. Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans. J Antimicrob Chemother 42:461–467. https://doi.org/10.1093/jac/42.4.461.
4. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. 2010. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 54: 804–810. https://doi.org/10.1128/AAC.01190-09.
5. Walker R, Andes D, Conklin J, Ebert S, Craig WA. 1994. Pharmacodynamic activities of meropenem in an animal infection model, abstr A91. Abstr 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL.
6. Louie A, Liu W, Fikes S, Brown D, Drusano GL. 2013. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother 57: 2788–2792. https://doi.org/10.1128/AAC.02624-12.
7. Macvane SH, Crandon JL, Nicolau DP. 2014. Characterizing in vivo pharmacodynamics of carbapenems against Acinetobacter baumannii in a murine thigh infection model to support breakpoint determinations. Antimicrob Agents Chemother 58:599–601. https://doi.org/10.1128/AAC.02029-13.
8. Li C, Kuti JL, Nightingale CH, Nicolau DP. 2006. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 46:1171–1178. https://doi.org/10.1177/0091270006291035.
9. Drusano GL, Lode H, Edwards JR. 2000. Meropenem: clinical response in relation to in vitro susceptibility. Clin Microbiol Infect 6:185–194. https://doi.org/10.1046/j.1469-0691.2000.00062.x.
10. Nicolau DP. 2008. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 47:S32–S40. https://doi.org/10.1086/590064.
11. Bhavani SM, Dudley MN, Landersdorfer C, Drusano GL, Craig WA, Jones RN, Ambrose PG. 2010. Pharmacokinetic-pharmacodynamic (PK_PD) basis for CLSI carbapenem (CARB) susceptibility breakpoint changes, abstr A1-1382. Abstr 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA.
12. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. 2003. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 43:1116 –1123. https://doi.org/10.1177/0091270003257225.
13. Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sorgel F, Jones RN, Drusano GL, Bertino JS, Jr. 2010. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis 68:251–258. https://doi.org/10.1016/j.diagmicrobio.2010.06.012.
14. Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN. 2015. Discovery of a cyclic boronic acid -lactamase inhibitor (RPX7009) with utility versus class A serine carbapenemases. J Med Chem 58:3682–3692. https://doi.org/10.1021/acs.jmedchem.5b00127.
15. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, Atlanta, GA.
16. Sabet M, Tarazi Z, Rubio-Aparicio D, Nolan TG, Parkinson J, Lomovskaya O, Dudley MN, Griffith DC. 2018. Activity of simulated human dosage regimens of meropenem and vaborbactam against carbapenem-resistant Enterobacteriaceae in an in vitro hollow-fiber model. Antimicrob Agents Chemother 62:e01969-17. https://doi.org/10.1128/AAC.01969-17.
17. Sabet M, Tarazi Z, Nolan T, Parkinson J, Rubio-Aparicio D, Lomovskaya O, Dudley MN, Griffith DC. 2017. Activity of meropenem-vaborbactam in mouse models of infection due to KPC-producing carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 62: e01446-17. https://doi.org/10.1128/AAC.01446-17.
18. Berkhout J, Melchers MJ, van Mil AC, Seyedmousavi S, Lagarde CM, Schuck VJ, Nichols WW, Mouton JW. 2016. Pharmacodynamics of ceftazidime and avibactam in neutropenic mice with thigh or lung infection. Antimicrob Agents Chemother 60:368 –375. https://doi.org/10.1128/AAC .01269-15.
19. VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Oku-sanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenber-gen JN, Ambrose PG. 2013. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother 57:2809–2814. https://doi.org/10.1128/AAC.02513-12.
20. Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Oku-sanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenber-gen JN, Ambrose PG. 2016. Pharmacokinetics-pharmacodynamics of tazobactam in combination with piperacillin in an in vitro infection model. Antimicrob Agents Chemother 60:2075–2080. https://doi.org/10.1128/AAC.02747-15.
21. Ambrose PG, VanScoy BD, Trang M, McCauley-Miller J, Conde H, Bhavnani SM, Alexander DC, Friedrich LV. 2017. Pharmacokinetics-pharmacodynamics of CB-618 in combination with cefepime, ceftazidime, ceftolozane and meropenem: the pharmacological basis for a stand-alone -lactamase inhibitor. Antimicrob Agents Chemother 61: e00630-17. https://doi.org/10.1128/AAC.00630-17.
22. Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. 2005. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:4920–4927. https://doi.org/10.1128/AAC.49.12 .4920-4927.2005.
23. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 10th ed. CLSI document M7-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
24. Bilello JA, Bauer G, Dudley MN, Cole GA, Drusano GL. 1994. Effect of 2’,3’-didehydro-3’-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob Agents Chemother 38:1386–1391. https://doi.org/10.1128/AAC.38.6.1386.
25. McSharry JJ, Weng Q, Brown A, Kulawy R, Drusano GL. 2009. Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother 53:2375–2381. https://doi.org/10.1128/AAC.00167-09.
26. Rubino CM, Bhavnani SM, Loutit JS, Morgan EE, White D, Dudley MN, Griffith DC. 2018. Phase 1 study of the safety, tolerability, and pharmacokinetics vaborbactam and meropenem alone and in combination following single and multiple doses in healthy adult subjects. Antimicrob Agents Chemother 62:e02228-17. https://doi.org/10.1128/AAC.02228-17.